Maria Q. Baggstrom
YOU?
Author Swipe
View article: Racialized Economic Segregation and Disparities in Non-Small Cell Lung Cancer Care and Outcomes
Racialized Economic Segregation and Disparities in Non-Small Cell Lung Cancer Care and Outcomes Open
Living in segregated, low-income NHB counties had adverse impacts on early detection, treatment, and outcomes of NSCLC. However, residential segregation did not explain the excess risks of NSCLC care underutilization and mortality in NHB p…
View article: Table S1 from Racialized Economic Segregation and Treatment and Outcomes of Small Cell Lung Cancer
Table S1 from Racialized Economic Segregation and Treatment and Outcomes of Small Cell Lung Cancer Open
The overall and race-specific associations between racialized economic segregation and all-cause mortality in non-Hispanic White and non-Hispanic Black patients with small cell lung cancer
View article: Table S1 from Racialized Economic Segregation and Treatment and Outcomes of Small Cell Lung Cancer
Table S1 from Racialized Economic Segregation and Treatment and Outcomes of Small Cell Lung Cancer Open
The overall and race-specific associations between racialized economic segregation and all-cause mortality in non-Hispanic White and non-Hispanic Black patients with small cell lung cancer
View article: Data from Racialized Economic Segregation and Treatment and Outcomes of Small Cell Lung Cancer
Data from Racialized Economic Segregation and Treatment and Outcomes of Small Cell Lung Cancer Open
Background:Little is known about the role of residential segregation in the treatment and outcomes of small cell lung cancer (SCLC), a highly recalcitrant disease, among non-Hispanic White (NHW) and non-Hispanic Black (NHB) patients.Method…
View article: Data from Racialized Economic Segregation and Treatment and Outcomes of Small Cell Lung Cancer
Data from Racialized Economic Segregation and Treatment and Outcomes of Small Cell Lung Cancer Open
Background:Little is known about the role of residential segregation in the treatment and outcomes of small cell lung cancer (SCLC), a highly recalcitrant disease, among non-Hispanic White (NHW) and non-Hispanic Black (NHB) patients.Method…
View article: Racialized Economic Segregation and Treatment and Outcomes of Small Cell Lung Cancer
Racialized Economic Segregation and Treatment and Outcomes of Small Cell Lung Cancer Open
Background: Little is known about the role of residential segregation in the treatment and outcomes of small cell lung cancer (SCLC), a highly recalcitrant disease, among non-Hispanic White (NHW) and non-Hispanic Black (NHB) patients. Meth…
View article: Investing in Women Trainees: Building a Women in Medicine Group at an Academic Institution
Investing in Women Trainees: Building a Women in Medicine Group at an Academic Institution Open
Given the importance of proactively supporting women trainees in medicine to address gender inequities, we draw on the experience of a well-established professional development initiative to provide a framework for other institutions seeki…
View article: Investing in Women Trainees: Building a Women in Medicine Group at an Academic Institution (Preprint)
Investing in Women Trainees: Building a Women in Medicine Group at an Academic Institution (Preprint) Open
UNSTRUCTURED Given the importance of proactively supporting women trainees in medicine to address gender inequities, we draw on the experience of a well-established professional development initiative to provide a framework for other inst…
View article: A phase II study of everolimus in patients with advanced solid malignancies with TSC1, TSC2, NF1, NF2 or STK11 mutations
A phase II study of everolimus in patients with advanced solid malignancies with TSC1, TSC2, NF1, NF2 or STK11 mutations Open
Although this study failed to meet its prespecified ORR threshold for success of 30% or higher, exploratory analyses suggest potential activity for everolimus in a subset of patients with lung adenocarcinomas with STK11 or NF1 mutations. F…
View article: Third-generation chemotherapy agents in the treatment of advanced non-small cell lung cancer: A meta-analysis [2]
Third-generation chemotherapy agents in the treatment of advanced non-small cell lung cancer: A meta-analysis [2] Open
No Abstract.
View article: Effect of Erlotinib Plus Bevacizumab vs Erlotinib Alone on Progression-Free Survival in Patients With Advanced<i>EGFR</i>-Mutant Non–Small Cell Lung Cancer
Effect of Erlotinib Plus Bevacizumab vs Erlotinib Alone on Progression-Free Survival in Patients With Advanced<i>EGFR</i>-Mutant Non–Small Cell Lung Cancer Open
ClinicalTrials.gov identifier: NCT01532089.
View article: Randomized Phase II Trial of Seribantumab in Combination with Erlotinib in Patients with EGFR Wild-Type Non-Small Cell Lung Cancer
Randomized Phase II Trial of Seribantumab in Combination with Erlotinib in Patients with EGFR Wild-Type Non-Small Cell Lung Cancer Open
Background Seribantumab (MM-121) is a fully human IgG2 monoclonal antibody that binds to human epidermal growth factor receptor 3 (HER3/ErbB3) to block heregulin (HRG/NRG)-mediated ErbB3 signaling and induce receptor downregulation. This o…
View article: A randomized phase II trial of erlotinib or erlotinib and bevacizumab in patients with advanced EGFR mutant non-small cell lung cancer (NSCLC)
A randomized phase II trial of erlotinib or erlotinib and bevacizumab in patients with advanced EGFR mutant non-small cell lung cancer (NSCLC) Open
Background: A retrospective subset analysis from a phase 3 trial, and preclinical data supported prospective study of elrotinib and bevacizumab in patients (pts) with EGFR mutant NSCLC. Methods: Pts were required to have an EGFR exon 19 de…
View article: Phase III Randomized, Placebo-Controlled, Double-Blind Trial of Celecoxib in Addition to Standard Chemotherapy for Advanced Non–Small-Cell Lung Cancer With Cyclooxygenase-2 Overexpression: CALGB 30801 (Alliance)
Phase III Randomized, Placebo-Controlled, Double-Blind Trial of Celecoxib in Addition to Standard Chemotherapy for Advanced Non–Small-Cell Lung Cancer With Cyclooxygenase-2 Overexpression: CALGB 30801 (Alliance) Open
Purpose Tumor overexpression of cyclooxygenase-2 (COX-2) has been associated with worse outcome in non–small-cell lung cancer (NSCLC). In Cancer and Leukemia Group B (CALGB) 30203, we found that the selective COX-2 inhibitor celecoxib in a…
View article: Delayed nausea and vomiting from carboplatin doublet chemotherapy
Delayed nausea and vomiting from carboplatin doublet chemotherapy Open
Without prophylactic aprepitant administration, 30% of patients receiving carboplatin containing regimen had moderate to severe delayed CINV.
View article: A Phase I Trial of Temsirolimus and Pemetrexed in Patients with Advanced Non-Small Cell Lung Cancer
A Phase I Trial of Temsirolimus and Pemetrexed in Patients with Advanced Non-Small Cell Lung Cancer Open
Background: Pemetrexed is an antifolate chemotherapeutic agent approved for use in non-small cell lung cancer (NSCLC). The mammalian target of rapamycin (mTOR) pathway is implicated in lung cancer development and inhibited by temsirolimus.…